Sanofi's Libtayo Lands In EU With Skin Cancer Nod
Nine months after the US approval, the EU has followed suit and given a conditional approval for Sanofi and Regeneron’s IO Libtayo for a, so far, untreatable skin cancer.
You may also be interested in...
BCC is the second non-melanoma skin cancer for which Libtayo has demonstrated efficacy as the PD-1 inhibitor, which also recently impressed in a lung cancer study, is already approved for cutaneous squamous cell carcinoma.
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
Pfizer and AstraZeneca were seeking National Health Service funding for the same indication for their respective lung cancer drugs. With "responsible pricing" after an initial rejection, Pfizer prevailed.